Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Aurelio Teleman honored with 2015/2016 Johann Georg Zimmermann-Prize

No. 05c | 03/02/2016

For over 40 years now, the Deutsche Hypothekenbank AG (Deutsche Hypo) has awarded the Johann Georg Zimmermann Prize to honor outstanding scientific achievements in the field of cancer research. This year’s award goes to Aurelio Teleman from the German Cancer Research Center (DKFZ). Aurelio, a biochemist, is studying molecular signaling pathways that regulate metabolism in cells. Defects in these signaling pathways can lead to cancer.


Aurelio Teleman is studying signaling pathways that control growth and metabolism in cells. Cellular growth uses a large portion of the energy that is supplied by metabolism. Therefore, these two processes must happen in a mutually coordinated way. Dysfunctional signaling chains can lead to cancer or metabolic diseases such as obesity and diabetes. For example, the insulin signaling pathway is significantly more active than normal in about 80 percent of all cancer cases.

Teleman’s goal is to find targets that may be used for treating metabolic disorders as well as cancer. During their studies, Teleman and colleagues recently discovered a fundamentally new metabolic pathway. They discovered that a fatty acid (stearic acid) that had previously been considered to be a simple metabolic product also has signaling functions. In their publication in the specialist journal “Nature”, the researchers demonstrate in flies as well as in cancer cells that stearic acid regulates the performance of mitochondria. These organelles serve as powerhouses of the cell.

When the researches added stearic acid to fly food, the animals’ mitochondria fused and performed well; when they kept fatty acid levels low, the organelles fragmented. The investigators subsequently studied flies that exhibit Parkinson's-like symptoms resulting from a mitochondrial defect and are recognized as a model system for studying this neurodegenerative disease. When the affected animals were fed stearic acid with their food, their motor skills and energy balance improved and they survived for much longer. Teleman is now exploring the question of whether stearic acid might also improve mitochondrial functioning in humans.

Born in the United States, Aurelio Teleman studied biochemistry at Harvard University, where he graduated in 1998. For his PhD studies, he moved to London Imperial College and subsequently to EMBL in Heidelberg, where he earned his PhD in 2004 and continued his research work for another year. Starting from 2007, Teleman headed a junior research group at the DKFZ; since 2012, he has been a research department head.

The Deutsche Hypo has awarded the Johann Georg Zimmermann Prize for over 40 years. Its goal is to support excellent scientific work in cancer research. In collaboration with Hannover Medical School (MHH), numerous German and international researchers have since then been honored for outstanding achievements in the fight against cancer.

The award will be presented jointly by the Chairman of the Board of Managing Directors of Deutsche Hypo, the donor of the prize, and the President of Hannover Medical School at a festive ceremony in Hanover on February 2, 2016.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS